About us
Carthera® is a spin-off company stemming from Assistance Publique Hôpitaux de Paris (AP-HP). Our team is made up of talented and ambitious scientists, world-renowned clinicians and industry experts committed to a common goal: Revolutionize the prospects for the treatment of brain disease.
A team of experts dedicated to patient health
We are working to transform the future of patients suffering from brain tumors and other serious brain diseases, through the development of innovative therapeutic solutions based on ultrasound technology.
Carthera® relies on the in-depth knowledge, experience and dynamism of leading experts from the medtech, biotech and clinical research communities to carry out its development projects. To find out more about the Carthera team, please consult the About Us page on our carthera.eu website.
The company is ISO 13485 certified for the design, development and production of its medical devices.
Carthera, initiator of the SonoCloud project
Carthera® has developed SonoCloud®, a revolutionary medical device that emits ultrasound to temporarily increase the permeability of blood vessels in the brain.
SonoCloud® technology has been developed for a wide range of brain disorders. Oncology indications (glioblastoma, brain metastases) are the company’s main target, but research is also underway for other conditions including neurodegenerative diseases, in particular Alzheimer’s disease.
Our scientific publications
Numerous preclinical and clinical papers have demonstrated the potential of low-intensity pulsed ultrasound (LIPU) to deliver therapeutic molecules to the brain.
Below are two relevant publications featuring the SonoCloud system.
“Repeated Blood-Brain Barrier Opening with a Nine-Emitter Implantable Ultrasound Device in Combination with Carboplatin in Recurrent Glioblastoma: a Phase I/II Clinical Trial”, published in the journal Nature.
“Safety and Feasibility of Repeated and Transient Blood-Brain Barrier Disruption by Pulsed Ultrasound in Patients with Recurrent Glioblastoma”, published in American Association for Cancer Research.
